This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Cardiogen
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict NOT-RELEVANT LOW
"For this user (20yo MMA athlete, no cardiac pathology, intact myocardium): the entire claimed use case — cardiac tissue support, post-MI recovery, age-related cardiomyopathy adjunct — does not exist in this profile. Khavinson family broad skepticism applies (zero Western replication, single-source evidence, contested mechanism). Even if every Khavinson claim were true, Cardiogen would have nothing to act on in a 20-year-old healthy athlete's heart. NOT-RELEVANT (rather than SKIP-FOR-NOW) reflects that this isn't a \"weigh evidence vs. risk\" question — it's a \"no indication exists\" question. Confidence is LOW because the underlying compound's evidence base is itself low-confidence; we're certain it's irrelevant for users in this archetype, less certain it does anything for anyone."
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | NOT-RELEVANT | No cardiac indication exists; cardiovascular system is intact at peak athletic capacity; Cardiogen has no claimed benefit in this profile. Cerebrolysin / Semax / Adamax already cover the brain-protective peptide role for this demographic. Cardiogen earns no slot. |
30-50, executive maintenance, no cardiac symptoms | NOT-RELEVANT | Cardiac risk-factor management belongs to lifestyle (cardio, sleep, BP/lipid management) and guideline-directed therapy if labs trigger it. Cardiogen has zero evidence base to compete with statins, ACE inhibitors, omega-3s, or exercise. |
50+, mild age-related cardiac decline (no clinical disease) | OPTIONAL | experimental. If running an existing comprehensive Khavinson stack (Epithalon + Pinealon + Vesugen), adding Cardiogen during one cycle to "complete the family" is defensible as a curiosity. Real cardiac risk reduction comes from cardio fitness, BP/lipid control, sleep, not Cardiogen. |
Post-MI / post-cardiac-event, in active cardiac rehab | OPTIONAL | adjunct, not substitute. Russian clinical tradition uses AEDR as adjunct to standard post-MI care. Western-evidence-graded therapies (dual antiplatelet, beta-blocker, ACEI/ARB, statin, cardiac rehab exercise) remain first-line and dominate Cardiogen on every measurable outcome. If pursuing peptide adjunct in this context, do so with cardiology supervision — not DIY, not for self-experimentation. |
Chronic heart failure (NYHA II-IV) | OPTIONAL | adjunct only with cardiology supervision. Same logic as above. Guideline-directed medical therapy (GDMT) for HF — beta-blocker, MRA, ARNI/ACEI, SGLT2 inhibitor — has overwhelming evidence. Cardiogen has none comparable. |
Anxiety-prone / sleep-disordered / strength-anabolic / recovery-focused | NOT-RELEVANT | Not in Cardiogen's claimed lane. |
High athletic load, tested status | N | on WADA prohibited list as of 2026 (S0 "non-approved substances" clause could theoretically be invoked, but Cardiogen specifically has no listing). Untested (the user): irrelevant — no use case anyway. |
- ★20-30, brain-priority, high cognitive workload (this-archetype)NOT-RELEVANT
No cardiac indication exists; cardiovascular system is intact at peak athletic capacity; Cardiogen has no claimed benefit in this profile. Cerebrolysin / Semax / Adamax already cover the brain-protective peptide role for this demographic. Cardiogen earns no slot.
- 30-50, executive maintenance, no cardiac symptomsNOT-RELEVANT
Cardiac risk-factor management belongs to lifestyle (cardio, sleep, BP/lipid management) and guideline-directed therapy if labs trigger it. Cardiogen has zero evidence base to compete with statins, ACE inhibitors, omega-3s, or exercise.
- 50+, mild age-related cardiac decline (no clinical disease)OPTIONAL
experimental. If running an existing comprehensive Khavinson stack (Epithalon + Pinealon + Vesugen), adding Cardiogen during one cycle to "complete the family" is defensible as a curiosity. Real cardiac risk reduction comes from cardio fitness, BP/lipid control, sleep, not Cardiogen.
- Post-MI / post-cardiac-event, in active cardiac rehabOPTIONAL
adjunct, not substitute. Russian clinical tradition uses AEDR as adjunct to standard post-MI care. Western-evidence-graded therapies (dual antiplatelet, beta-blocker, ACEI/ARB, statin, cardiac rehab exercise) remain first-line and dominate Cardiogen on every measurable outcome. If pursuing peptide adjunct in this context, do so with cardiology supervision — not DIY, not for self-experimentation.
- Chronic heart failure (NYHA II-IV)OPTIONAL
adjunct only with cardiology supervision. Same logic as above. Guideline-directed medical therapy (GDMT) for HF — beta-blocker, MRA, ARNI/ACEI, SGLT2 inhibitor — has overwhelming evidence. Cardiogen has none comparable.
- Anxiety-prone / sleep-disordered / strength-anabolic / recovery-focusedNOT-RELEVANT
Not in Cardiogen's claimed lane.
- High athletic load, tested statusN
on WADA prohibited list as of 2026 (S0 "non-approved substances" clause could theoretically be invoked, but Cardiogen specifically has no listing). Untested (the user): irrelevant — no use case anyway.
▸ Subjective experience (deep)
Onset: Days to weeks, if any. Not an acute-effect compound.
Peak / character: Most users describe nothing perceptible across a 20-30 day cycle. A minority report subtle "cardiac" subjective effects — perceived exercise tolerance, "easier breathing" during cardio, calmer resting heart sensation. None biomarker-confirmed; all consistent with placebo.
Characteristic absences:
- No stimulant effect, no jitter, no appetite change
- No noticeable acute "feel" within an hour of dose
- No crash on cessation
For this archetype (20yo combat athlete, intact cardiovascular system, athletic resting HR, no cardiac pathology): expect nothing subjectively detectable. The case for Cardiogen, if made for anyone, is on cardiac-aging or post-injury-recovery grounds — neither applies.
▸ Tolerance + cycling deep dive
- Tolerance buildup: Unknown / not characterized.
- Recommended cycle: Khavinson canonical — 1 month oral course, repeat every 3-6 months. Injectable: 2-4 weeks on, 3-6 months off.
- No physical dependence, no withdrawal.
▸ Stacking deep dive
Synergistic with (theoretical, not demonstrated)
- Other Khavinson organ-specific bioregulators — Cardiogen + Pinealon + Epithalon + Vesugen is the textbook Khavinson "comprehensive longevity protocol" framing. Theoretical only; no head-to-head data showing additive benefit; running multiple Khavinson peptides simultaneously stacks the same single-source-evidence problem multiplicatively.
- BPC-157 / TB-500 — pep-pedia lists "theoretical synergy" via complementary tissue-repair mechanisms. Pure narrative; no published combination studies. BPC-157 has its own evidence-quality issues; combining two thinly-evidenced peptides does not produce strong evidence.
- Conventional cardiac medications — listed as "monitor combination" by pep-pedia. For a 20yo with no cardiac disease, this is irrelevant.
Avoid stacking with
- Other Khavinson tetrapeptides simultaneously (AEDR/Cardiogen, AEDG/Epithalon, EDR/Pinealon, KE/Thymogen, KED/Vesugen, etc.) — running multiple at once makes attribution impossible and stacks the single-source-evidence problem. Pick one per cycle if you're pursuing the family at all.
- Active cancer / known malignancy. Pro-survival, p53-suppressive in cardiomyocyte context. Default to caution.
- Active anabolic / pro-proliferative growth-factor stacks (high-dose IGF-1, GH). Pep-pedia flags this as "monitor for excessive fibroblast activation." Theoretical; no characterized interaction.
Neutral / safe co-administration
- the canonical stack base stack (citicoline, Mg L-threonate, NAC, fish oil, PS, rhodiola, theanine, B-complex) — no interaction expected.
- Creatine, modafinil, caffeine — no interaction expected.
▸ Drug interactions deep dive
- No documented CYP induction/inhibition. Tetrapeptide metabolized by peptidases, not CYP enzymes.
- No documented interactions with Russian peptides a user in this archetype would stack (Semax, Adamax, Cerebrolysin, Selank, Bromantane).
- Theoretical: additive with conventional cardiac drugs. Russian clinical practice claims compatibility; no characterized interactions; no PK data.
- Theoretical: pro-proliferative additive with growth factors. Flagged by pep-pedia. Practical impact in a 20yo not running anabolics: zero.
▸ Pharmacogenomics
- None established. No published polymorphism-stratified data for Cardiogen response.
- Speculative (untested): Cardiac-relevant variants (e.g., MYBPC3, MYH7, ACE I/D, AGT, eNOS) could in principle modulate response if the "cardiac bioregulator" claim is real. None tested. Not actionable.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Gray-market Russian (oral capsule) | CosmicNootropic (Cardiogen® bioregulator) | ~$40-60 / 60 caps (1-month course) | High | NPCRIZ-manufactured; legitimate Russian consumer product; room-temp stable. Easiest to source if anyone trials it. |
| Gray-market Russian (oral capsule) | RUPharma (Cardiogen) | Comparable to CosmicNootropic | High | Same Russian manufacturer. Trustpilot reputation strong. |
| Research-chem (injectable) | CosmicPeptides / Peptide Sciences / BiotechPeptides | ~$50-80 / 20 mg vial | Medium-High | Lyophilized; cold storage and reconstitution. COA quality varies. Verify >97% HPLC purity, AEDR sequence confirmation, mass spec data. |
Cold chain
- Oral capsule: Room temperature, <25°C, dry, dark. No special handling.
- Injectable (lyophilized vial): Store -20°C dry, dark, before reconstitution. After reconstitution, refrigerate at 2-8°C, use within ~30 days.
Sourcing strategy for users in this archetype
Don't. No use case. If for some reason a cardiac indication later emerges (it shouldn't, at his age and athletic profile), oral capsule from CosmicNootropic / RUPharma is the lowest-friction path — but the prerequisite question is "why are we running this at all?" not "where do we buy it?"
▸ Biomarkers to track (deep)
Only if running it for an actual cardiac indication. For the user profile, the better answer is "don't run it, so no biomarker tracking needed for this compound."
If running with actual cardiac indication:
- Baseline: ECG, lipid panel, hsCRP, BP, resting HR. Echo if HF concern. Troponin only if recent event. NT-proBNP if HF concern.
- During use: Symptom tracking (chest pain, palpitations, exercise tolerance VAS); no mid-cycle labs typically needed unless symptoms change.
- Post-cycle: Repeat baseline panel 1-2 weeks post-cessation. Look for any movement in inflammatory markers / lipids / BNP if applicable. Non-movement is the expected null result.
▸ Controversies / open debates Live debate
- Khavinson family overall legitimacy. Same critique as the rest of the family. >300 papers across the bioregulator-peptide family over 40 years, but zero independent Western replication, near-total absence from ClinicalTrials.gov, methodology inconsistent with modern RCT standards, commercial conflict of interest. Honest framing: not "obvious quackery," but not "established medicine" either.
- The "one peptide, one organ" pattern. Cardiogen (heart) + Bronchogen (lung) + Prostamax (prostate) + Pancragen (pancreas) + Cerluten (liver) + Vesugen (vasculature) + Pinealon (brain) + Epithalon (pineal/telomerase) follows a branding-friendly partition of biology by organ. Real transcription factors have overlapping tissue expression, share targets across organ systems, and don't cleanly correspond to vendor product lines. The pattern raises priors that the framework is product-positioning-shaped rather than biology-shaped.
- Cardiogen's internal data direction is mixed. Pro-proliferative / anti-apoptotic in cardiomyocytes (2009 myocardial culture paper); pro-apoptotic in M-1 sarcoma (2009 tumor paper). Both effects in the same compound, in different tissues, is biologically possible — but the convenience of "good thing in target tissue, opposite good thing in tumor tissue" is a marketing-friendly outcome.
- No Western interest. Unlike Cerebrolysin (which has hundreds of independent papers and Western-quality RCTs in stroke) and Cortexin (which has at least some independent Russian replication outside Khavinson), Cardiogen has produced essentially no signal that has prompted Western cardiology to follow up. That absence-of-interest is itself a weak negative signal — Western cardiology is well-funded and would notice a real cardiomyocyte-protective small molecule.
- The dose-universe contradiction (microgram oral vs. milligram injectable) is unresolved. Either most research-chem injectable users are massively over-dosing, or the Russian oral product is sub-therapeutic. No PK data resolves this. Research-peptide community defaults to milligram dosing across the Khavinson family, which is internally inconsistent with the Russian framework's microgram-scale claims.
▸ Verdict change log
- 2026-05-06 — Initial verdict: NOT-RELEVANT / verdict-confidence LOW. No cardiac indication exists for users in this archetype (20yo combat athlete, intact myocardium, no risk factors). Khavinson family broad skepticism applies. The compound's evidence base is thin Russian-only, single-source, no independent replication. NOT-RELEVANT (rather than SKIP-FOR-NOW) reflects that this is a "no indication" case, not a "weigh evidence vs. risk" case. Confidence is LOW because the underlying compound's evidence is itself low-confidence — we're highly certain it's irrelevant for users in this archetype, less certain whether it does anything for anyone.
▸ Open questions / gaps Open
- Is there any independent (non-Khavinson) cardiac study on AEDR? Periodic re-search recommended — if a Western group publishes on AEDR cardiomyocyte effects, the verdict for the broader population (not the user) changes.
- What is the actual peptide content per RUPharma / CosmicNootropic capsule? Russian product transparency on actual peptide content per capsule is limited; "AKS-K peptide complex" labeling does not disclose the exact AEDR amount per capsule with full transparency.
- What is the correct dose universe — microgram (Russian) or milligram (research-chem)? No published human PK resolves this. The 0.05 ng/ml in vitro effective concentration favors the microgram framework.
- Is the threefold mortality reduction in coronary ligation models reproducible? This is the most provocative in vivo finding for Cardiogen but the primary publication trail is hard to follow in PubMed; needs deeper sourcing if the question becomes relevant.
- Does the user ever need this? Only if cardiac pathology develops at age 35+, and even then guideline-directed therapy dominates. Practical answer: no.
▸ Cross-references
- [[cerluten]] — Khavinson liver/lung-targeted bioregulator. Same family, same critique. Even thinner evidence base than Cardiogen.
- [[vesugen]] — Khavinson tripeptide KED, "vascular bioregulator." Same family, same critique. Vesugen is the closest "use-case neighbor" to Cardiogen for anyone framing cardiovascular intervention via Khavinson peptides. Both NOT-RELEVANT for users in this archetype.
- [[prostamax]] — Khavinson tetrapeptide AEDG (Ala-Glu-Asp-Gly), prostate-targeted. Sister compound by structural analogy (single amino-acid swap from AEDR). Different organ target, same framework.
- [[adalank]] — Khavinson adrenal-cortex-targeted bioregulator (not yet built). Same family.
- [[cartalax]] — Khavinson cartilage-targeted tetrapeptide. Same family. Listed in pep-pedia as "compatible" with Cardiogen in comprehensive Khavinson protocols.
- [[testagen]] — Khavinson testis-targeted bioregulator. Same family, same critique.
- [[epithalon]] — Khavinson tetrapeptide AEDG (Ala-Glu-Asp-Gly) — flagship of the family, by far the most-studied; pineal/telomerase axis. Cardiogen rides on the family's reputation but does not contribute its own evidence base.
- [[pinealon]] — Khavinson tripeptide EDR. Currently WATCH-LIST for users in this archetype (mechanism more developed). Cardiogen does not reach that bar — no profile-relevant indication.
References
Khavinson V.Kh., Lin'kova N.S., et al. (2012). Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins. Bull Exp Biol Med 153(4):559-562. PMID 22977870
Chalisova N.I., Lesniak V.V., et al. (2009). The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Adv Gerontol 22(3):409-413. PMID 20210190
Levdik N.V., Knyazkin I.V. (2009). Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med 148(3):433-436. PMID 20396706
Zakutskii A.N., Chalisova N.I., et al. (2006). The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Adv Gerontol 19:93-96. PMID 17152728
Kheifets O.V., Polyakova V.O., Kvetnoy I.M. (2010). Peptidergic regulation of the expression of signal factors of fibroblast differentiation. Adv Gerontol 23(1):68-70. PMID 20586252
Khavinson V.Kh. (2002). Peptides and aging. Neuroendocrinol Lett 23(Suppl 3):11-144. PMID 12163170
Atlas of Science (2023). Cardiomyocyte metabolism research and Cardiogen peptide.
Khavinson-network review citing the coronary ligation mouse model.
View SourceCosmicNootropic Cardiogen® product page
Russian oral capsule, NPCRIZ manufacturer.
View SourcePep-pedia Cardiogen entry
locally mirrored at `pep-pedia-mirror/site/peptides/cardiogen.html`.
View SourcePPInteractions8 compounds▸
| Peptide | Status | Note |
|---|---|---|
BPC-157 | Synergistic | Theoretical synergy based on complementary mechanisms - Cardiogen supports cardiac tissue while BPC-157 promotes healing in gut and soft tissues. No published combination studies exist. |
TB-500 | Synergistic | Theoretical synergy based on complementary mechanisms - TB-500 promotes blood vessel formation and broad tissue repair while Cardiogen provides heart-specific support. No published combination studies exist. |
Pinealon | Compatible | Complementary Khavinson bioregulators targeting different organ systems. Pinealon supports neuroprotection while Cardiogen targets cardiac tissue. Routinely combined in Russian longevity protocols. |
Cartalax | Compatible | Fellow Khavinson bioregulator targeting cartilage and connective tissue. Different tissue specificity allows combination without overlap. Used together in comprehensive anti-aging protocols. |
Thymosin Alpha-1 | Compatible | Thymosin Alpha-1 supports immune modulation while Cardiogen targets cardiac tissue. Different mechanisms with no known interactions. May complement each other in recovery protocols. |
Epitalon | Synergistic | Theoretical synergy through complementary pathways. Epitalon activates telomerase and regulates pineal function while Cardiogen supports cardiac tissue maintenance. Combined in Russian geroprotective protocols but no published combination studies exist. |
Conventional Cardiovascular Medications | Monitor Combination | Russian clinical practice uses Cardiogen alongside conventional treatments for heart conditions. Monitor cardiovascular parameters when combining with existing cardiac medications. |
Growth Factors (IGF-1, HGH) | Monitor Combination | Both affect tissue proliferation pathways. Monitor for excessive fibroblast activation or unexpected tissue changes when combining growth-promoting compounds. |
PP Community insights — click to load ▸
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.